Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.45 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4255720 | 0.90 | ALDH1A1 (0.54) | LPAR1ALDH1A1LMNATLR2MAPK1 | |
| SCHEMBL31752535 | 0.85 | HTT (0.51) | LPAR1ALDH1A1LMNATLR2MAPK1 | |
| SCHEMBL4285855 | 0.85 | ALDH1A1 (0.49) | LPAR1ALDH1A1LMNAMAPK1L3MBTL1 | |
| SCHEMBL19300948 | 0.85 | ALDH1A1 (0.68) | LPAR1ALDH1A1LMNATLR2PRKCA | |
| SCHEMBL20793332 | 0.84 | ALDH1A1 (0.54) | LPAR1ALDH1A1LMNATLR2MAPK1 | |
| SCHEMBL4078739 | 0.84 | MAPK1 (0.48) | ALDH1A1LMNATLR2MAPK1PRKCA | |
| SCHEMBL4077674 | 0.84 | ALDH1A1 (0.48) | LPAR1ALDH1A1LMNATLR2MGLL | |
| SCHEMBL24677830 | 0.81 | ALDH1A1 (0.58) | ALDH1A1LMNAMAPK1L3MBTL1MGLL | |
| SCHEMBL5386843 | 0.81 | ALDH1A1 (0.58) | ALDH1A1LMNAMAPK1L3MBTL1MGLL | |
| SCHEMBL318699 | 0.81 | ALDH1A1 (0.58) | ALDH1A1LMNAMAPK1L3MBTL1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221684-A1 | Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221684-A1 | Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof | ANXA6, STING1, ADM2 | LPAR1 1907/4885ALDH1A1 2863/4885LMNA 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.